Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replicel Life Sciences Inc (OP: REPCF )

0.0002 UNCHANGED
Streaming Delayed Price Updated: 2:36 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replicel Life Sciences Inc

RepliCel Provides Corporate Update
Via ACCESSWIRE
RepliCel Announces Material Patent Milestones in Key Markets
Via ACCESSWIRE
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
Via ACCESSWIRE
RepliCel’s Manufacturing Inspected by Japan’s PMDA
After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel’s Manufacturing Inspected by Japan’s PMDA
Via ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
Via ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
Via ACCESSWIRE
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces Material Patent Milestones
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc.... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
RepliCel Closed Final Tranche of Strategic Investment Commitment
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Terminates License Agreement with Shiseido
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc.... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces Dermal Injector Update
Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE /... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC /... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Economy
Exposures Economy
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
- Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 /... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Adds Independent Director
Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2),... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
RepliCel Launches Testing of Dermal Injector Units
Initial units delivered and first phase of functional testing nearly complete VANCOUVER, BC / ACCESSWIRE / May 25, 2021 / RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF) (FRA:P6P2) ("RepliCel" or... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, will lead RepliCel's Skin Rejuvenation Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimization VANCOUVER, BC / ACCESSWIRE / May 11, 2021 / RepliCel Life... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
RepliCel Announces Record Year in Patents Granted
Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 3,... 
From RepliCel Life Sciences, Inc.
Via AccessWire
RepliCel Closes Second Tranche of Strategic Investment Commitment
MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP)... 
From RepliCel Life Sciences, Inc.
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.